Free Trial

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories logo
$132.59 +1.22 (+0.93%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$132.50 -0.09 (-0.07%)
As of 08/29/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
18

Based on 22 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 4 have given a hold rating, 16 have given a buy rating, and 2 have given a strong buy rating for ABT.

Consensus Price Target

$144.47
8.97% Upside
According to the 22 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $144.47. The highest price target for ABT is $160.00, while the lowest price target for ABT is $130.00. The average price target represents a forecasted upside of 8.97% from the current price of $132.59.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

TypeCurrent Forecast
8/30/24 to 8/30/25
1 Month Ago
7/31/24 to 7/31/25
3 Months Ago
6/1/24 to 6/1/25
1 Year Ago
8/31/23 to 8/30/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
14 Buy rating(s)
7 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$144.47$144.47$142.59$121.80
Forecasted Upside8.97% Upside14.52% Upside6.66% Upside7.53% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside8.97% Upside15,803.52% Upside10.22% Upside
News Sentiment Rating
Positive News

See Recent ABT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/18/2025Wells Fargo & Company
3 of 5 stars
Lawrence Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$147.00 ➝ $142.00+14.26%
7/18/2025Raymond James Financial
4 of 5 stars
Jayson Bedford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$142.00 ➝ $141.00+13.29%
7/18/2025BTIG Research
2 of 5 stars
Marie Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$148.00 ➝ $145.00+20.08%
7/18/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Taylor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$143.00 ➝ $145.00+20.08%
7/17/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeStrong-Buy
7/16/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$130.00 ➝ $140.00+6.54%
7/15/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$145.00 ➝ $147.00+12.31%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Lewis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$127.00 ➝ $137.00+3.75%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$140.00 ➝ $145.00+8.52%
6/16/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$143.00+5.61%
4/17/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Adam Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00+9.98%
4/17/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt Miksic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$158.00 ➝ $159.00+21.71%
4/17/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rick Wise
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$135.00 ➝ $145.00+11.76%
3/10/2025Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Travis Steed
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$133.00 ➝ $150.00+8.03%
3/4/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joanne Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$135.00 ➝ $160.00+15.20%
3/4/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Roman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$138.00 ➝ $154.00+9.70%
1/28/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
1/23/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Danielle Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$146.00 ➝ $148.00+25.68%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$133.00 ➝ $138.00+17.37%
10/8/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$130.00+14.69%
9/19/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$131.00+14.04%
7/30/2024Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:27 PM ET.


Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 26, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • The company reported a quarterly revenue of $11.14 billion, exceeding analyst estimates, indicating strong financial performance and potential for growth.
  • Abbott Laboratories has a solid return on equity of 18.32%, which suggests effective management and profitability relative to shareholder equity.
  • The current stock price is around $134.55, reflecting a stable investment opportunity in the healthcare sector.
  • With a net margin of 32.43%, Abbott Laboratories demonstrates efficient cost management and profitability, which can lead to higher returns for investors.
  • The company has set a positive FY 2025 guidance for earnings per share (EPS) between 5.100-5.200, indicating expected growth in profitability.

Abbott Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • Insider ownership is relatively low at 0.46%, which may raise concerns about alignment between management and shareholder interests.
  • Recent insider selling by the CFO, who sold 5,550 shares, could signal potential concerns about the company's future performance.
  • Analysts have mixed ratings, with some recent price target reductions, indicating uncertainty in the stock's future performance.
  • The dividend payout ratio is 29.57%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Market volatility in the healthcare sector could impact Abbott Laboratories' stock performance, making it a riskier investment in uncertain economic conditions.

ABT Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $144.47, with a high forecast of $160.00 and a low forecast of $130.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 8.97% based on their 12-month stock forecasts.

Over the previous 90 days, Abbott Laboratories's stock had 3 upgrades by analysts.

Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.91 while the average consensus rating score for "medical" companies is 2.78. Learn more on how ABT compares to other companies.


This page (NYSE:ABT) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners